We believe to create transformative therapies, you need a commitment to a deep understanding of disease. MyoKardia is pioneering a precision medicine approach to discover, develop and commercialize targeted therapies for the treatment of serious cardiovascular diseases.

Overview

MyoKardia’s scientists have discovered a portfolio of small molecule therapeutics aimed at the muscle proteins of the heart and intended to correct the excessive contraction, impaired relaxation or insufficient contraction underlying diseases of systolic and diastolic dysfunction. We are applying a precision medicine approach to develop our therapeutic candidates for patient populations with shared characteristics, such as causal genetic mutations or disease subtypes. Our clinical-stage pipeline includes: mavacamten (formerly 461) in Phase 3 and Phase 2 clinical trials for hypertrophic cardiomyopathies (HCM); MYK-491 in Phase 2 for patients with stable heart failure; and MYK-224, in Phase 1 development for HCM. MyoKardia maintains global rights to all its programs.

Our leadership

Tassos Gianakakos

Chief Executive Officer

Tassos Gianakakos

Chief Executive Officer

Tassos Gianakakos joined MyoKardia in October 2013, bringing more than 17 years of senior leadership experience and business development and finance expertise in the biopharmaceutical industry to the company. He joined MyoKardia from MAP Pharmaceuticals (acquired by Allergan in March 2013), where he was most recently senior vice president and chief business officer. In this position, Mr. Gianakakos played an integral role in advancing the company’s two Phase 3 clinical programs and regulatory filings for LEVADEX®, and led the successful co-promotion partnership agreement for the program with Allergan, as well as a global partnership with AstraZeneca for the company’s Unit Dose Budesonide program. Prior to MAP, Mr. Gianakakos led the formation of Codexis, Inc., a spin-off of Maxygen, Inc., in 2001. At Codexis, Mr. Gianakakos served as president and senior vice president, business development, and global head of Codexis' Pharmaceuticals Business Unit. Before forming Codexis, Mr. Gianakakos was director of business development at Maxygen, where he led the company’s business development efforts for its vaccine and bio-industrial platforms, as well as financing activities including the company’s initial public offering. Prior to Maxygen, Mr. Gianakakos was a process engineer in Merck & Co.’s vaccine division.
Mr. Gianakakos holds B.Sc. degrees in chemical engineering and economics from the Massachusetts Institute of Technology, an M.Sc. in biotechnology from Northwestern University and an M.B.A. from Harvard Business School.

close
William Fairey

Executive Vice President, Chief Commercial Officer

William Fairey

Executive Vice President, Chief Commercial Officer

William C. Fairey joined MyoKardia in January 2019, as Chief Commercial Officer and Executive Vice President with nearly three decades of biopharmaceutical industry experience building and leading patient-focused and science-driven organizations. Most recently, he served as the Chief Operating Officer and Executive Vice President of ChemoCentryx, Inc., where he led the company’s commercial strategy, including the development and execution of commercialization plans for avacopan and CCX140.  Prior to ChemoCentryx, Mr. Fairey held global leadership positions with Actelion Pharmaceuticals over a period of seventeen years, most recently serving as President of Actelion Pharmaceuticals U.S. Inc., overseeing more than 400 employees and $1.5 billion in net sales in 2017 before its acquisition by Johnson & Johnson for $30 billion. At Actelion US, he helped the company gain FDA approvals and launch OPSUMIT and UPTRAVI for pulmonary arterial hypertension and VALCHLOR for cutaneous T-cell lymphoma.  Mr. Fairey also served as President of Actelion Canada and as Regional Vice President of Australia Asia Pacific, where he had oversight across the region, including founding Actelion’s first affiliates in China, Taiwan and Singapore.  Before taking on the Canadian role, Mr. Fairey was Vice President of Sales and Managed Markets in the US, where he built Actelion’s first sales and managed markets teams and established the strategies and systems to support the launch of Actelion’s first product, TRACLEER.  Before joining Actelion, Mr. Fairey held a number of commercial roles during his 12 years with Parke-Davis Pharmaceuticals US.  
Mr. Fairey holds a bachelor’s degree in Biology from the University of Oregon and earned a Master of Business Administration degree from Saint Mary’s College of California. 

close
June Lee, MD

Executive Vice President, Chief Development Officer

June Lee, MD

Executive Vice President, Chief Development Officer

June Lee, M.D., has significant experience leading early clinical development programs and is also a recognized leader in academic translational research. Dr. Lee is an adjunct professor at the University of California, San Francisco (UCSF) School of Medicine, where she formerly served as Director of Translational Research and Director of Catalyst Program which is an internal accelerator at UCSF for early stages technologies in therapeutics, devices, diagnostics, and digital health. A key focus of Dr. Lee’s work was identifying the most compelling discovery research and enabling and supporting its commercialization. Previously, she worked in early clinical development in cardiovascular, metabolism, respiratory, and infectious diseases at Genentech. Dr. Lee serves as chair of the Board of Directors for the Council of Korean Americans. She is also a member of the Translational Research Advisory Council of the MOGAM Research Institute, and the MTRAC for Life Sciences Innovation Hub Therapeutic/Diagnostic Oversight Committee, a unit associated with The University of Michigan Medical School.
Dr. Lee completed her undergraduate work in chemistry at the Johns Hopkins University, earned her M.D. degree at the School of Medicine at University of California, Davis, and her clinical training in internal medicine and pulmonary/critical care and UCLA and UCSF.

close
Robert McDowell, PhD

Chief Scientific Officer

Robert McDowell, PhD

Chief Scientific Officer

Robert McDowell has over three decades of experience discovering small molecule drugs in cardiovascular disease, inflammation and oncology, with seven compounds advancing into clinical trials. Dr. McDowell has been an integral part of MyoKardia since its inception in 2012, having served as Senior Vice President of Drug Discovery through October 2017, when he was promoted to his current position. Prior to joining MyoKardia, Dr. McDowell led drug discovery at 3-V Biosciences, advancing the company's lead program into development. He previously served as vice president of research at Sunesis Pharmaceuticals, where he oversaw drug discovery, translational research and manufacturing functions. Dr. McDowell led the structural chemistry group at Axys Pharmaceuticals. Before joining Axys, Dr. McDowell was a senior scientist at Genentech, where he developed successful strategies for peptidomimetic design. Dr. McDowell has authored more than 40 peer-reviewed manuscripts and is an inventor on more than 20 issued U.S. patents.
Dr. McDowell holds a B.S. in chemistry and physics from Butler University and a Ph.D. in chemistry from the University of California at Berkeley.

close
Jake Bauer

Chief Business Officer

Jake Bauer

Chief Business Officer

Jake Bauer brings more than 15 years of biopharma industry experience.  He is currently responsible for corporate and business development, program management, portfolio strategy, alliance management, and corporate strategy functions.  From July 2014 to April 2018, he also led the finance, accounting, information technology, facilities, corporate communications, and investor relations functions as senior vice president, finance and corporate development.  
He joined MyoKardia from Ablexis, LLC, where he was vice president, business operations and head of corporate development. At Ablexis, he led the development and implementation of the company’s corporate strategy and business development activities and oversaw business operations. Prior to Ablexis Mr. Bauer was a principal at Third Rock Ventures, wherehe was actively involved in a variety of leading biopharmaceutical companies including Agios, CytomX, Global Blood Therapeutics and Zafgen. Prior to Third Rock Ventures, Mr. Bauer served in roles in the investment group at Royalty Pharma, the business development group at Endo Pharmaceuticals, and was previously a management consultant at Putnam Associates.
Mr. Bauer holds a B.Sc. in biology and a B.A. in economics from Duke University and an M.B.A. from Harvard Business School. He currently serves on the board of directors of Phoenix Tissue Repair.

close
Taylor Harris

Chief Financial Officer

Taylor Harris

Chief Financial Officer

Taylor C. Harris brings more than 20 years of finance and life science industry experience to MyoKardia where he leads the finance, accounting, information technology, facilities, corporate communications and investor relations functions.
Previously, Mr. Harris most served as Senior Vice President and Chief Financial Officer of Zeltiq Aesthetics, Inc., until that company’s acquisition by Allergan plc.  During that time, he was responsible for global finance, accounting, tax, treasury, investor relations, and information technology functions, as well as the company’s commercial operations, including customer service, product support, and inside sales.  Prior to Zeltiq, Mr. Harris served as Vice President and Chief Financial Officer at Thoratec Corporation (acquired by St. Jude Medical, Inc.).  Prior to joining Thoratec, Mr. Harris worked at JPMorgan Chase & Co. for over a decade in several capacities, including as a Vice President in the firm's Healthcare Investment Banking and Equity Research departments.  
Mr. Harris holds a Bachelor of Arts in Physics and Economics from the University of North Carolina at Chapel Hill, where he studied as a Morehead-Cain Scholar.

close
Cynthia Ladd

General Counsel

Cynthia Ladd

General Counsel

Ms. Ladd joins MyoKardia having most recently served as senior vice president and general counsel for CytomX Therapeutics, Inc.  Before joining CytomX in 2015, she was an independent consultant to biotechnology companies (including CytomX), supporting corporate growth by advising on corporate strategy, negotiations around collaborations, and clinical and regulatory issues, as well as acting as general counsel. Prior to her consultancy, she was president and chief executive officer of AGY Therapeutics, leading the company through a successful venture round and its transition to a clinical organization. Ms. Ladd also served as senior vice president and general counsel at Pharmacyclics, where she led various operating groups, including regulatory affairs, advised on corporate governance and compliance, structured negotiations for business development activities and led all the legal activities, including those related to the company’s intellectual property portfolio.  Earlier in her career, Ms. Ladd held a number of positions at Genentech, including vice president of corporate law and chief corporate counsel. 
Ms. Ladd began her career as an associate with Wilson, Sonsini, Goodrich & Rosati and Ware & Freidenrich (now DLA Piper).  She received her law degree from Stanford Law School, a master’s degree in animal nutrition and biochemistry from Cornell University and a bachelor’s degree in animal science from Pennsylvania State University.

close
Ingrid Boyes

Senior Vice President, Human Resources

Ingrid Boyes

Senior Vice President, Human Resources

Ingrid Boyes has more than 20 years of human resources and senior leadership experience across the insurance, banking and biotech industries. Prior to MyoKardia, Ms. Boyes was vice president and head of human resources for global product development at Roche. In this role, she was responsible for leading the human resources strategy globally for that function. Previously, she was at Genentech, where she held positions of increasing responsibility, including director of corporate staffing and diversity. She was also senior director of human resources for technical operations and prior to that, held a similar role leading human resources for North America commercial operations. 
Ms. Boyes holds a B.S. from the University of San Francisco and an MBA from Notre Dame de Namur University.

close
Marc Semigran, MD

Senior Vice President, Medical Sciences

Marc Semigran, MD

Senior Vice President, Medical Sciences

Marc Semigran, M.D., joined MyoKardia in December, 2016. Previously, he led the Massachusetts General Hospital Heart Failure and Cardiac Transplant Program as section head and medical director, from 2004 to 2016. In addition, he was principal investigator of the Harvard Regional Clinical Center of the National Heart, Lung, and Blood Institute Heart Failure Network. Dr. Semigran was a member of the internal medicine and cardiology staff of Massachusetts General for more than 25 years and is an associate professor at Harvard Medical School. He has published more than 140 peer-reviewed papers in cardiomyopathy, heart failure and cardiac transplantation, and served as editor for a leading textbook on heart failure. Dr. Semigran is a recipient of numerous National Institutes of Health and industry research awards, and has served as principal or co-investigator in several major clinical trials across various therapeutic areas. In addition, he has served in scientific and medical advisory capacities to such companies as GSK, Medtronic plc and Bayer.
Dr. Semigran earned A.B., A.M. and M.D. degrees from Harvard University. He completed his internal medicine residency and cardiology fellowship training at Massachusetts General.

close
Jay Edelberg, MD, PhD

Senior Vice President, Clinical Development

Jay Edelberg, MD, PhD

Senior Vice President, Clinical Development

Dr. Edelberg is a clinical cardiologist and vascular biologist, having served in leadership roles for two decades in both academic medicine and the biopharmaceutical industry. Most recently, Dr. Edelberg led cardiovascular drug development at Sanofi, where he spearheaded the development of Praluent® and oversaw the clinical development and global project teams involved in the MyoKardia partnership. Previously, Dr. Edelberg directed cardiovascular biomarker research at Bristol-Myers Squibb, where he served as the U.S. medical lead for Eliquis® and at Glaxo SmithKline.
From 1999 to 2006, Dr. Edelberg served as an attending coronary care unit (CCU) cardiologist and directed the Cardiac Vascular Biology Research Laboratory at Weill-Cornell Medical Center, with a specific research focus on cardiac stems cells and biomarkers of cardiac aging. Dr. Engelberg trained at the Massachusetts General Hospital (Internal Medicine), the Beth Israel Deaconess Medical Center in Boston (Cardiovascular Medicine) and Massachusetts Institute of Technology (Biology). Dr. Edelberg is an M.D., Ph.D., graduate of Duke University in Durham, North Carolina. 

close
Joseph Lambing, PhD

Senior Vice President, Nonclinical & Pharmaceutical Development

Joseph Lambing, PhD

Senior Vice President, Nonclinical & Pharmaceutical Development

Joe Lambing, Ph.D., has more than 20 years of drug development experience in the areas of cardiovascular disease, inflammation and oncology. During his career, Dr. Lambing has contributed to numerous NDA and IND filings for more than a dozen new chemical entities, as well as numerous filings to support a variety of clinical trials in other countries. Prior to joining MyoKardia, he was senior vice president of development for Portola Pharmaceuticals, where he oversaw all preclinical and pharmaceutical development activities since the company’s founding in 2003. Prior to Portola, Dr. Lambing served as director of drug safety and disposition for Millennium Pharmaceuticals’ San Francisco site, and director of DMPK and toxicology at COR Therapeutics.
Dr. Lambing holds a B.S. in chemistry and a Ph.D. in biochemistry from the University of Missouri, and was a postdoctoral fellow at the University of California, San Diego.

close

Our Board of Directors

Sunil Agarwal, MD

Independent Director

Sunil Agarwal, MD

Independent Director

Sunil Agarwal, M.D., is president of research and development at Juno Therapeutics. Previously, he was a partner in Sofinnova, a Menlo Park, Ca. based biotech-focused investment firm. He is also a former executive vice president and chief medical officer for Ultragenyx Pharmaceutical, where he managed the company's clinical development and operations, regulatory affairs, biometrics, pharmacovigilance, medical affairs, pharmacology and toxicology. Dr. Agarwal served in various leadership roles at Genentech for more than a decade, including senior vice president and global head of clinical development for ophthalmology, metabolism, neurosciences, immunology and infectious diseases. He led the approval of multiple therapies at Genentech including RITUXAN®, ACTEMRA®, LUCENTIS® and XOLAIR®. Earlier in his career, Dr. Agarwal was at MedImmune and Guilford Pharmaceuticals, where he served in both development and medical affairs, and led the formation of the medical affairs organization for Guilford. He completed his residency at Children’s National Medical Center (CNMC), Washington, D.C., and practiced in the CNMC Pediatric Emergency Department. He has served on the faculty at George Washington University School of Medicine as Assistant Clinical Professor of Pediatrics.
Dr. Agarwal obtained a B.S. in neurobiology at Cornell University, and earned his M.D. from Tufts University School of Medicine.

close
Mary Cranston

Independent Director

Mary Cranston

Independent Director

Mary Cranston joined MyoKardia as an independent director in April 2016. Ms. Cranston is a retired senior partner of Pillsbury Winthrop Pittman LLP, an international law firm. She was formerly chair and chief executive officer of Pillsbury.
Ms. Cranston currently serves as a director of Visa Inc., The Chemours Company and CSAA Insurance. She is also the chair of the board of the Stanford Children's Hospital and Children's Health Network. She previously served as a member of the boards of Juniper Networks, International Rectifier Corporation, Exponent, Inc. and GrafTech International, Inc., and is a former member of the Stanford University Board of Trustees. Ms. Cranston has been recognized by the National Law Journal as one of the 100 Most Influential Lawyers in America.
Ms. Cranston holds both A.B. and J.D. degrees from Stanford University.

close
Tassos Gianakakos

Chief Executive Officer

Tassos Gianakakos

Chief Executive Officer

Tassos Gianakakos joined MyoKardia in October 2013, bringing more than 17 years of senior leadership experience and business development and finance expertise in the biopharmaceutical industry to the company. He joined MyoKardia from MAP Pharmaceuticals (acquired by Allergan in March 2013), where he was most recently senior vice president and chief business officer. In this position, Mr. Gianakakos played an integral role in advancing the company’s two Phase 3 clinical programs and regulatory filings for LEVADEX®, and led the successful co-promotion partnership agreement for the program with Allergan, as well as a global partnership with AstraZeneca for the company’s Unit Dose Budesonide program. Prior to MAP, Mr. Gianakakos led the formation of Codexis, Inc., a spin-off of Maxygen, Inc., in 2001. At Codexis, Mr. Gianakakos served as president and senior vice president, business development, and global head of Codexis' Pharmaceuticals Business Unit. Before forming Codexis, Mr. Gianakakos was director of business development at Maxygen, where he led the company’s business development efforts for its vaccine and bio-industrial platforms, as well as financing activities including the company’s initial public offering. Prior to Maxygen, Mr. Gianakakos was a process engineer in Merck & Co.’s vaccine division.
Mr. Gianakakos holds B.Sc. degrees in chemical engineering and economics from the Massachusetts Institute of Technology, an M.Sc. in biotechnology from Northwestern University and an M.B.A. from Harvard Business School.

close
David Meeker, M.D.

Independent Director

David Meeker, M.D.

Independent Director

David Meeker, M.D., is executive vice president and head of Sanofi Genzyme, the specialty care global business unit of Sanofi that focuses on rare diseases, multiple sclerosis, oncology, and immunology. As executive vice president of Sanofi, he served as a member of the executive committee. Dr. Meeker joined Genzyme in 1994 and held positions of increasing responsibility including vice president, medical affairs, chief operating officer and ultimately president and chief executive officer. Prior to joining Genzyme, Dr. Meeker was director of the Pulmonary Critical Care Fellowship at the Cleveland Clinic and an assistant professor of medicine at The Ohio State University. He has authored more than 40 articles and multiple book chapters.
Dr. Meeker received his M.D. degree from the University of Vermont Medical School. He completed the Advanced Management Program at Harvard Business School in 2000.

close
Mark Perry

Independent Director

Mark Perry

Independent Director

Mark Perry is a biotech veteran with more than 30 years of industry experience. Mr. Perry has served as an entrepreneur-in-residence at Third Rock Ventures and as president, chief executive officer and director of Aerovance, Inc., a biotechnology company focused on the development of human therapeutics for respiratory and allergic diseases. From 1994 to 2007, Mr. Perry served in several executive roles at Gilead Sciences, Inc., including executive vice president of operations, as well as general counsel and chief financial officer. Earlier in his career, Mr. Perry was a partner of Cooley LLP, where he maintained a corporate and securities practice with an emphasis on biotechnology and high technology companies, investment banks and venture capital partnerships. He currently serves as chairman of the board of Global Blood Therapeutics and director of Nvidia Corporation. Mr. Perry is also a member of the California State Bar Association and the Association of Bioscience Financial Officers, and serves on several nonprofit boards.
Mr. Perry holds a B.A. from the University of California, Berkeley and a J.D. from the University of California, Davis.

close
Kim Popovits

Independent Director

Kim Popovits

Independent Director

Kim Popovits has been widely recognized for her contributions to science and the commercialization of the biotechnology industry. Ms. Popovits has been Genomic Health’s chairman of the board since 2012, and chief executive officer and president since 2009. She served as president and chief operating officer since joining the company in 2002. Previously, Ms. Popovits spent 15 years at Genentech, where she led the successful commercialization of 14 new therapies. Before joining Genentech, Ms. Popovits served as division manager for American Critical Care, a division of American Hospital Supply Corporation. She currently serves on the boards of American Clinical Laboratory Association, California Life Sciences Association, Personalized Medicine Coalition, and ZS Pharma. She is president of The Coalition for 21st Century Medicine and serves as an advisor to the Healthcare Businesswomen’s Association. 
Ms. Popovits holds a B.A. degree in business from Michigan State University.

close
Wendy Yarno

Independent Director

Wendy Yarno

Independent Director

Wendy Yarno held positions of increasing responsibility over a 26-year career at Merck & Co, Inc., leading multiple business groups. Most recently, she served as chief marketing officer, leading the global organization charged with all aspects of pre-and post-launch commercialization of pharmaceuticals in more than 20 therapeutic areas. Ms. Yarno also served as Merck’s senior vice president of human resources, where her successful efforts to develop and implement new corporate HR strategies proved transformative for this key business function. Previously, Ms. Yarno was vice president of the Johnson & Johnson Co. unit Ortho McNeil Pharmaceutical’s highly profitable Women’s Health Care Franchise. Ms. Yarno has served on the boards of ADial Pharmaceuticals, Durata Therapeutics, Medivation, St. Jude Medical, and PluroGen Therapeutics.
Ms. Yarno received an M.B.A. from the Fox School of Business at Temple University and a B.S. in business administration from Portland State University.

close

Our History

MyoKardia was founded in 2012 by Third Rock Ventures and four scientific leaders in their respective fields, Leslie Leinwand, PhD, at the BioFrontiers Institute at the University of Colorado, Christine Seidman, MD, with Harvard Medical School and Brigham and Women’s Hospital, Jonathan Seidman, PhD, also from Harvard Medical School, and James Spudich, PhD, with Stanford University.

Together, they shared a vision that there was a lack of therapeutic innovation in treating cardiovascular disease – the number one cause of death globally. Leveraging their diverse expertise in company formation, myosin motors and heart muscle function, and genetics, MyoKardia was formed to discover and develop novel therapeutics that could address the underlying biomechanical cause of disease for well-defined patient populations.

Timeline of MyoKardia's Corporate History

what's happening

Life at MyoKardia